Schedule 13G ownership disclosure

ONCOLYTICS BIOTECH INC

Common Stock, no par value · CUSIP: 682310875

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Anson Funds Management LP

    Shares: 8,185,743 · Class: 9.6%

  • Anson Management GP LLC

    Shares: 8,185,743 · Class: 9.6%

  • Tony Moore

    Shares: 8,185,743 · Class: 9.6%

  • Anson Advisors Inc.

    Shares: 8,185,743 · Class: 9.6%

  • Amin Nathoo

    Shares: 8,185,743 · Class: 9.6%

  • Moez Kassam

    Shares: 8,185,743 · Class: 9.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-021601
Form type
SCHEDULE 13G
Filer
Anson Funds Management LP
CIK
CIK 1491072
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub